A meeting with the doctors and employees of 8 leading South Korean clinical and university centers was held in Seoul. It was related to the Phase 3 clinical trials conducted as part of the global registration program for Olokizumab.
The event was attended by the team of Quintiles IMS, a partner organization of R-Pharm Group for conducting the trials. It is important to note that R-Pharm is the first Russian company conducting clinical trials in South Korea.
The participants discussed the current status of patient enrollment for the clinical trials program to investigate Olokizumab in patients with rheumatoid arthritis (CREDO), innovative screening methods, use of electronic medical records and particular aspects of conducting the trials in patients in Asia.
“Such meetings are very important for our joint activities, and we sincerely hope that our partnership with foreign researchers will develop further in future. Together, we will do our best to make Olokizumab available to patients across the globe as quickly as possible. In close collaboration with representatives of Korean clinical centers and universities, we are actively using the modern approaches to research, including the latest advances in digital medicine,” said Mikhail Samsonov, the Director of Medical Department at R-Pharm.